Sana Biotechnology logo
Sana Biotechnology
SANA | NASDAQ
Chart Builder DCF Calculator
$1.88
-$0.14 (-6.93%)
At close: Nov 16, 2026, 4:00 PM ET
$1.88
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:41 PM ET

Sana Biotechnology Company Profile

Company profile explained

Company Profile

Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.

Key Executives

Name Position
Steven D. Harr President, Chief Executive Officer & Director
Aaron Grossman Executive VP, Chief Legal Officer & Corporate Secretary
Brian D. Piper Executive Vice President & Chief Financial Officer
Debra Wisdom VP & Head of People
Dhavalkumar D. Patel Executive Vice President & Chief Scientific Officer
Gary Meininger Executive VP & Chief Medical Officer
John Gerecitano Senior Vice President, Clinical Lead, Hematology & Oncology Development
Snehal Patel Executive VP & Chief Technical Officer
Susan Wyrick Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting
Yuko Soneoka SVP & Head of Intellectual Property

Latest SEC Filings

Date Type Title
Oct 06, 2026 4 Filing
Sep 08, 2026 8-K Current Report
Aug 27, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 10, 2026 10-Q Quarterly Report
Aug 10, 2026 8-K Current Report
Jul 07, 2026 4 Filing
Jun 05, 2026 4 Filing
Jun 05, 2026 4 Filing
Jun 05, 2026 4 Filing
View All SEC Filings ➞
Sana Biotechnology
Sana Biotechnology logo
Country United States
IPO Date Feb 4, 2021
Industry Biotechnology
Sector Healthcare
Employees 142
CEO Steven D. Harr

Contact Details

188 East Blaine Street Seattle, Washington 98102 United States

Stock Details

Ticker Symbol SANA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001770121
CUSIP Number 799566104
ISIN Number US7995661045
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.